In this presentation from “Lymphoma and Myeloma 2015: An International Congress on Hematologic Malignancies”, Dr. Giorgio Inghirami discusses whether or not we can use patient-derived xenografts to assess new lymphoma therapies. A continuing education program is offered as a supplement to this webcast at the following location: http://elc.imedex.com/ELC/Activity-Search.aspx?search=LM2015EP © 2015 Imedex, LLC.
Author: admin
In this presentation from “Lymphoma and Myeloma 2015: An International Congress on Hematologic Malignancies”, Dr. Irene M. Ghobrial discusses why Waldenstrom’s and myeloma change from monoclonal gammopathy of undetermine significane (MGUS) to active disease. A continuing education program is offered as a supplement to this webcast at the following location: http://elc.imedex.com/ELC/Activity-Search.aspx?search=LM2015EP © 2015 Imedex, LLC.
In this presentation from “Lymphoma and Myeloma 2015: An International Congress on Hematologic Malignancies”, Dr. Esteban Braggio discusses how useful genomics is in the clinical practice, with regard to the treatment of chronic lymphocytic leukemia (CLL). A continuing education program is offered as a supplement to this webcast at the following location: http://elc.imedex.com/ELC/Activity-Search.aspx?search=LM2015EP © 2015 Imedex, LLC.
In this presentation from “Lymphoma and Myeloma 2015: An International Congress on Hematologic Malignancies”, Dr. Koen van Besien disccusses patient selection criterion for allogeneic transplant as treatment of chronic lymphocytic leukemia (CLL). A continuing education program is offered as a supplement to this webcast at the following location: http://elc.imedex.com/ELC/Activity-Search.aspx?search=LM2015EP © 2015 Imedex, LLC.
In this presentation from “Lymphoma and Myeloma 2015: An International Congress on Hematologic Malignancies”, Dr. John Allan discusses the risks, predictors, and treatment of Richter’s Syndrome. A continuing education program is offered as a supplement to this webcast at the following location: http://elc.imedex.com/ELC/Activity-Search.aspx?search=LM2015EP © 2015 Imedex, LLC.
In this presentation from “Lymphoma and Myeloma 2015: An International Congress on Hematologic Malignancies”, Dr. Jennifer R. Brown discusses whether the incidence of familial chronic lymphocytic leukemia (CLL) is increasing. A continuing education program is offered as a supplement to this webcast at the following location: http://elc.imedex.com/ELC/Activity-Search.aspx?search=LM2015EP © 2015 Imedex, LLC.
In this presentation from “Lymphoma and Myeloma 2015: An International Congress on Hematologic Malignancies”, Dr. Richard R. Furman elucidates the different between the various techniques of using CAR-T cells for the treatment of chronic lymphocytic leukemia (CLL) A continuing education program is offered as a supplement to this webcast at the following location: http://elc.imedex.com/ELC/Activity-Search.aspx?search=LM2015EP © 2015 Imedex, LLC.
In this presentation from “Lymphoma and Myeloma 2015: An International Congress on Hematologic Malignancies”, Dr. Mitchell R. Smith discusses when and how to use FCR and BR in the treatment of chronic lymphocytic leukemia (CLL). A continuing education program is offered as a supplement to this webcast at the following location: http://elc.imedex.com/ELC/Activity-Search.aspx?search=LM2015EP
In this presentation from “Lymphoma and Myeloma 2015: An International Congress on Hematologic Malignancies”, Dr. Steve Coutre discusses tyrosine-kinase inhibitors (TKIs), apoptotic enhancers, and other small molecules in the pipeline for the treatment of chronic lymphocytic leukemia (CLL). A continuing education program is offered as a supplement to this webcast at the following location: http://elc.imedex.com/ELC/Activity-Search.aspx?search=LM2015EP © 2015 Imedex, LLC.
In this presentation from “Lymphoma and Myeloma 2015: An International Congress on Hematologic Malignancies”, Dr. Richard R. Furman discusses risk assessment in the treatment of chronic lymphocytic leukemia (CLL). A continuing education program is offered as a supplement to this webcast at the following location: http://elc.imedex.com/ELC/Activity-Search.aspx?search=LM2015EP © 2016 Imedex, LLC.
In this presentation from “Lymphoma and Myeloma 2015: An International Congress on Hematologic Malignancies”, Dr. Kanti Rai discuses the most recently approved tyrosine-kinase inhibitors (TKIs) for the treatment of chronic lymphocytic leukemia (CLL). A continuing education program is offered as a supplement to this webcast at the following location: http://elc.imedex.com/ELC/Activity-Search.aspx?search=LM2015EP © 2016 Imedex, LLC.
In this presentation from “Lymphoma and Myeloma 2015: An International Congress on Hematologic Malignancies”, Dr. Neil Kay discusses the targeted inhibition of signal molecules as a novel therapy for the treatment of chronic lymphocytic leukemia (CLL). A continuing education program is offered as a supplement to this webcast at the following location: http://elc.imedex.com/ELC/Activity-Search.aspx?search=LM2015EP © 2016 Imedex, LLC.
In this presentation from “Lymphoma and Myeloma 2015: An International Congress on Hematologic Malignancies”, Dr. Kenneth C. Anderson discusses new paradigms and therapies for the treatment of relapsed/refracory myeloma. He discussesthe use fo small molecules and monoclonal antibodies. A continuing education program is offered as a supplement to this webcast at the following location: http://elc.imedex.com/ELC/Activity-Search.aspx?search=LM2015EP © 2016 Imedex, LLC.
In this presentation from “Lymphoma and Myeloma 2015: An International Congress on Hematologic Malignancies”, Dr. Guentehr Koehne examines whether there is a role for allotransplant in the treatment of myeloma. A continuing education program is offered as a supplement to this webcast at the following location: http://elc.imedex.com/ELC/Activity-Search.aspx?search=LM2015EP © 2016 Imedex, LLC.
In this presentation from “Lymphoma and Myeloma 2015: An International Congress on Hematologic Malignancies”, Dr. Sundar Jagannath argues against maintenance therapy in the myeloma setting. A continuing education program is offered as a supplement to this webcast at the following location: http://elc.imedex.com/ELC/Activity-Search.aspx?search=LM2015EP © 2016 Imedex, LLC.
In this presentation from “Lymphoma and Myeloma 2015: An International Congress on Hematologic Malignancies”, Dr. Antonio Palumbo argues in favor of the use of immunomodulatory drugs (IMiDs) for the maintenance of myeloma patients. A continuing education program is offered as a supplement to this webcast at the following location: http://elc.imedex.com/ELC/Activity-Search.aspx?search=LM2015EP © 2016 Imedex, LLC.
In this presentation from “Lymphoma and Myeloma 2015: An International Congress on Hematologic Malignancies”, Dr. James R. Berenson argues that myeloma patients should be maintained with proteasome inhibitors. A continuing education program is offered as a supplement to this webcast at the following location: http://elc.imedex.com/ELC/Activity-Search.aspx?search=LM2015EP © 2016 Imedex, LLC.
In this presentation from “Lymphoma and Myeloma 2015: An International Congress on Hematologic Malignancies”, Dr. Tomer Mark argues that it is not necessary for patients to achieve a complete remission (CR) and minimum residual disease (MRD), and that transplant is therefore unnecessary. A continuing education program is offered as a supplement to this webcast at the following location: http://elc.imedex.com/ELC/Activity-Search.aspx?search=LM2015EP © 2015 Imedex, LLC.
In this presentation from “Lymphoma and Myeloma 2015: An International Congress on Hematologic Malignancies”, Dr. Ajai Chari argues that it is necessary for patients to achieve a complete remission (CR) and minimum residual disease (MRD), and that transpant facilitates this. A continuing education program is offered as a supplement to this webcast at the following location: http://elc.imedex.com/ELC/Activity-Search.aspx?search=LM2015EP © 2015 Imedex, LLC.
In this presentation from “Lymphoma and Myeloma 2015: An International Congress on Hematologic Malignancies”, Dr. Antonio Palumbo discusses the best treatment options for transplant-ineligible myeloma patients, and whether those comprise two, three, or four drug regimens. A continuing education program is offered as a supplement to this webcast at the following location: http://elc.imedex.com/ELC/Activity-Search.aspx?search=LM2015EP © 2015 Imedex, LLC.
In this presentation from “Lymphoma and Myeloma 2015: An International Congress on Hematologic Malignancies”, Dr. David Roodman discusses the advances in both biology and the treatment of myeloma bone disease. A continuing education program is offered as a supplement to this webcast at the following location: http://elc.imedex.com/ELC/Activity-Search.aspx?search=LM2015EP © 2015 Imedex, LLC.
In this abstract presentation, Dr. Paul G. Richardson discusses the results of a mutlicenter Phase 2 trial on the use of ibrutinib in combination with low-dose dexamethasone in patients with relapsed or relapsed and refractory multiple meyloma. A continuing education program is offered as a supplement to this webcast at the following location: http://elc.imedex.com/ELC/Activity-Search.aspx?search=LM2015EP © 2015 Imedex, LLC.
In this presentation from “Lymphoma and Myeloma 2015: An International Congress on Hematologic Malignancies”, Dr. Renier J. Brentjens discusses the latest information on CARS and “armored” CARS as an immunological t-cell treatment of cancer. A continuing education program is offered as a supplement to this webcast at the following location: http://elc.imedex.com/ELC/Activity-Search.aspx?search=LM2015EP © 2015 Imedex, LLC.
In this presentation from “Lymphoma and Myeloma 2015: An International Congress on Hematologic Malignancies”, Dr. Jatin J. Shah discusses whether high-risk myeloma should be treated differently and how one should do so. A continuing education program is offered as a supplement to this webcast at the following location: http://elc.imedex.com/ELC/Activity-Search.aspx?search=LM2015EP © 2015 Imedex, LLC.
In this presentation from “Lymphoma and Myeloma 2015: An International Congress on Hematologic Malignancies”, Dr. C. Ola Landgren examines whether minimum residual disease (MRD) is a necessary clinical tool of evaluation in the treatment of myeloma. A continuing education program is offered as a supplement to this webcast at the following location: http://elc.imedex.com/ELC/Activity-Search.aspx?search=LM2015EP © 2015 Imedex, LLC.
In this presentation from “Lymphoma and Myeloma 2015: An International Congress on Hematologic Malignancies”, Dr. James R. Berenson discusses B-cell maturation antigen: a new biomarker for B-cell malignancies. A continuing education program is offered as a supplement to this webcast at the following location: http://elc.imedex.com/ELC/Activity-Search.aspx?search=LM2015EP
Carlos Fernandez de Larrea, MD, PhD from the Hospital ClÃnic de Barcelona, Barcelona, Spain gives an overview of his talk on response assessment in multiple myeloma (MM) held at the 2016 World Congress on Controversies in Multiple Myeloma (COMy) in Paris, France. According to Dr de Larrea, the response assessment in MM is crucial. It is important to establish whether a patient has achieved complete remission (CR) and to identify patients who are relapsing or progressing after different lines of treatment. Dr de Larrea further discusses the various techniques used to assess response, such as electrophoresis in serum and urine…
Do I need head and neck specialists for my cancer? Patient Power Founder and Host, Andrew Schorr, discusses this question with Head and Neck Oncologist Dr. Faye Johnson at MD Anderson Cancer Center. Although this question may seem obvious, Dr. Johnson stresses the importance of building a team that are head and neck oncology experts for the best possible rehabilitation and support. This team should include oncology, radiology, surgery, pathology, audiologist and/or speech therapy. Get email alerts | http://www.patientpower.info/alerts Subscribe on YouTube | http://www.youtube.com/patientpower Like on Facebook | http://www.fb.com/patientpower.info Follow on Twitter | http://www.twitter.com/patientpower Follow on Google+ | http://www.google.com/+patientpowerinfo
What are the targeted and less toxic treatments for head and neck cancers? Patient Power Founder and Host, Andrew Schorr, interviews Head and Neck Oncologist, Dr. Faye Johnson of The University of Texas MD Anderson Cancer Center in Houston. Dr. Johnson discusses four promising areas of targeted research in head and neck cancers, including immunotherapy and HPV. Dr. Johnson stresses that targeted therapies are best found in clinical trials and shares options on how patients can get connected. Get email alerts | http://www.patientpower.info/alerts Subscribe on YouTube | http://www.youtube.com/patientpower Like on Facebook | http://www.fb.com/patientpower.info Follow on Twitter | http://www.twitter.com/patientpower Follow on…
What exactly is MRD? Who should be tested? From the Myeloma 2016 meeting in Boston, Dr. Ola Landgren from Memorial Sloan Kettering Cancer Center explains MRD and what patients should be tested. He goes on to discuss how MRD and other diagnostic tests are being used by doctors in myeloma care, as well as updated guidelines for testing provided by the International Myeloma Working Group (IWMG). Get email alerts | http://www.patientpower.info/alerts Subscribe on YouTube | http://www.youtube.com/patientpower Like on Facebook | http://www.fb.com/patientpower.info Follow on Twitter | http://www.twitter.com/patientpower Follow on Google+ | http://www.google.com/+patientpowerinfo
How much of a difference in counts can you expect to see if you have blood drawn and processed at different labs? In this Ask the Expert segment, MPN expert Dr. Naveen Pemmaraju answers this question from viewer, Cindy. Dr. Pemmaraju discusses the variation in labs and offers tips to track your results, following trends versus the results of a single test. Get email alerts | http://www.patientpower.info/alerts Subscribe on YouTube | http://www.youtube.com/patientpower Like on Facebook | http://www.fb.com/patientpower.info Follow on Twitter | http://www.twitter.com/patientpower Follow on Google+ | http://www.google.com/+patientpowerinfo
Is stem cell transplant a viable treatment option? How long should maintenance therapy last? From the Myeloma 2016 meeting in Boston, myeloma expert Dr. Thomas Martin from UCSF Medical Center answered these questions and more related to myeloma treatment. He goes on to discuss new and upcoming myeloma treatments as well as the important role that research plays. Get email alerts | http://www.patientpower.info/alerts Subscribe on YouTube | http://www.youtube.com/patientpower Like on Facebook | http://www.fb.com/patientpower.info Follow on Twitter | http://www.twitter.com/patientpower Follow on Google+ | http://www.google.com/+patientpowerinfo
Patient Power Founder and Host, Andrew Schorr, discusses cancer screening with MD Anderson Cancer Centers Head and Neck Surgeon and Specialist, Dr. Erich Sturgis. Dr. Sturgis details the benefits of screening, particularly with the HPV vaccination. Screening allows specialists to identify cancer early enough in the process to increase the patients chance of successful treatment. Get email alerts | http://www.patientpower.info/alerts Subscribe on YouTube | http://www.youtube.com/patientpower Like on Facebook | http://www.fb.com/patientpower.info Follow on Twitter | http://www.twitter.com/patientpower Follow on Google+ | http://www.google.com/+patientpowerinfo
How do I manage my cancer pain? Patient Power Founder and Host, Andrew Schorr, interviews MD Anderson Cancer Center’s pain management specialist, Dr. David Hui. Dr. Hui has devoted his career to helping cancer patients find relief from their pain. Listen as he describes various types of pain and explains how to best manage your care and seek relief. Get email alerts | http://www.patientpower.info/alerts Subscribe on YouTube | http://www.youtube.com/patientpower Like on Facebook | http://www.fb.com/patientpower.info Follow on Twitter | http://www.twitter.com/patientpower Follow on Google+ | http://www.google.com/+patientpowerinfo
At the 2016 World Congress of the International Society of Hematology (ISH) held in Glasgow, Scotland, Paul Richardson, MD, from the Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA gives an overview of his talk on the latest advances in the clinical management of relapsed/refractory multiple myeloma (MM). He discusses several drugs that have been recently approved by the FDA in the US, namely pomalidomide, carfilzomib, the HDAC inhibitor panobinostat, elotuzumab, daratumumab, and ixazomib, which is the first oral proteasome inhibitor. According to Dr Richardson, these new drugs have had a dramatic effect on clinical management due to their novel…
At the 2016 Annual Meeting of the British Society of Haematology (BSH) and International Society of Hematology (ISH), held in Glasgow, Scotland. Keith Stewart, MB, ChB from the Mayo Clinic, Scottsdale, AZ gives an overview of a session on what the most appropriate approach to treating patients with relapsed myeloma. One of the key messages is the importance of using multiple drugs for treating multiple clones of the disease, according to Dr Stewart. He further discusses the combination of lenalidomide and dexamethasone as a backbone of carfilzomib, ixazomib and elotuzumab. According to Dr Stewart, randomized trials show that the combination…
What causes lung cancer? Can it be passed on genetically? Lung cancer experts Dr. George Simon of MD Anderson Cancer Center and Dr. Rebecca Heist of Harvard Medical Center discuss various common causes of lung cancer, including chemicals, pesticides and radon exposure. Dr. Simon concludes with screening options, including a new alternative to low-dose CAT scans. Get email alerts | http://www.patientpower.info/alerts Subscribe on YouTube | http://www.youtube.com/patientpower Like on Facebook | http://www.fb.com/patientpower.info Follow on Twitter | http://www.twitter.com/patientpower Follow on Google+ | http://www.google.com/+patientpowerinfo
In this Ask the Expert segment, Patient Power community member, Peggy, wrote, How strong of a connection is there between long-term use of Jakafi and non-melanoma skin cancer? Should a patient quit taking medication? MPN expert Dr. Naveen Pemmarju of MD Anderson Cancer Center responds with a discussion of a journal article and goes on to stress the importance of vigilance and monitoring.
As part of Patient Powers coverage of Myeloma 2016, several renowned multiple myeloma experts joined together to discuss what they learned at the meeting. Drs. Ken Anderson, Keith Stewart, Noopur Raje and Sagar Lonial, discuss how the Myeloma 2016 meeting fosters collaboration among myeloma researchers, from all over the world. The experts discuss new discoveries, genetics, combination therapies, as well as how technological changes are allowing increasing the pace of advances in the field. Get email alerts | http://www.patientpower.info/alerts Subscribe on YouTube | http://www.youtube.com/patientpower Like on Facebook | http://www.fb.com/patientpower.info Follow on Twitter | http://www.twitter.com/patientpower Follow on Google+ | http://www.google.com/+patientpowerinfo
Anna Schuh, MD, PhD, from the University of Oxford, UK, gives an overview of her talk on the advances in the molecular stratification of chronic lymphocytic leukemia (CLL). The focus of the talk was to make sense of the biological and clinical heterogeneity of CLL patients. The fludarabine, cyclophosphamide and rituximab (FCR) therapy is still the standard of care frontline treatment and while data shows that many patients respond very well or have even shown to be cured, around 25% of patients will relapse within the first two years of having received chemoimmunotherapy according to Dr Schuh. Molecular markers may…
Andrew Zelenetz, MD, PhD, from Memorial Sloan-Kettering Cancer Center, New York, NY gives an overview of the case studies on chronic lymphocytic leukemia (CLL) he presented at the 36th World Congress of the International Society of Hematology (ISH) held in Glasgow, Scotland. In the first case study, he discusses the use and side effect profiles of ibrutinib as well as idelalisib and rituximab. Dr Zelenetz also addresses the management of the side effects in his first case study. In the second case discussed, Dr Zelenetz discusses how the response to an alternative kinase inhibitor after progession is not very favorable.…
In this Ask the Expert video segment, multiple myeloma expert Dr. Jatin Shah of MD Anderson Cancer Center responds to a question about the reason why patients on multiple myeloma maintenance therapy are are advised to avoid antioxidants, particularly on medication day. Listen as Dr. Shah explains why high doses of vitamin C and green tea, as well as potential other antioxidants, are not recommended for patients on certain maintenance therapies. Get email alerts | http://www.patientpower.info/alerts Subscribe on YouTube | http://www.youtube.com/patientpower Like on Facebook | http://www.fb.com/patientpower.info Follow on Twitter | http://www.twitter.com/patientpower Follow on Google+ | http://www.google.com/+patientpowerinfo
With all of the advances in cancer research, where does the field of prostate cancer stand? Andrew Schorr, Patient Power Founder, speaks with genitourinary clinician and researcher, Dr. Russell Szmulewitz, about the latest prostate cancer updates. Dr. Szmulewitz is very hopeful based on hormone therapies, current medications, and the climate of collaboration among international researchers. Get email alerts | http://www.patientpower.info/alerts Subscribe on YouTube | http://www.youtube.com/patientpower Like on Facebook | http://www.fb.com/patientpower.info Follow on Twitter | http://www.twitter.com/patientpower Follow on Google+ | http://www.google.com/+patientpowerinfo
This was my talk at the University of Minnesota’s Masonic Cancer Center Seminar Series on May 10, 2016. I review translational approaches to cancer research, areas of cancer research that should be reassessed, and novel approaches to strategies that can be used in the lab to address clinically relevant questions in oncology. More information on my laboratory research and clinical work can be found on my UMN website: https://www.dom.umn.edu/divisions/hematology-oncology-and-transplantation/lou-lab
Ruben Mesa, MD, from the Mayo Clinic, Scottsdale, AZ, USA discusses current developments in myeloproliferative neoplasms (MPNs) at the 2016 Annual Meeting of the British Society of Haematology (BSH) and International Society of Hematology (ISH) held in Glasgow, Scotland. According to Dr Mesa, it is a very exciting time for MPNs as new JAK inhibitors such as pacritinib and NS-018, anti-fibrosing agents such as PRM-151 as well as telomerase inhibitors such as imetelstat, are being developed.
Ruben Mesa, MD, from the Mayo Clinic, Scottsdale, AZ, USA discusses how to manage adult myeloproliferative neoplasm (MPN) patients at the 2016 Annual Meeting of the British Society of Haematology (BSH) and International Society of Hematology (ISH) in Glasgow, Scotland. An understanding of the patients’ risk, molecular features and their symptom burden is key to assessing their treatment options. Dr Mesa further discusses the prevention of vascular events through the use of aspirin and cytoreduction.
Ruben Mesa, MD, from the Mayo Clinic, Scottsdale, AZ, USA provides an overview of his talk on individualizing care for myeloproliferative neoplasm (MPN) patients held at the 2016 Annual Meeting of the British Society of Haematology (BSH) and International Society of Hematology (ISH) in Glasgow, Scotland. The focus is on understanding the indvidual patient’s disease burden and risk for molecular features and devising a plan for the patient that includes the prevention of vascular events and the avoidance of disease progression. Dr Mesa also discusses some of the key considerations that need to be taken into account for each patient,…
Peter Hillmen, MD, PhD, from St. James’ University Hospital, Leeds, UK gives an overview of the RESONATE-2 trial (NCT01722487), a randomized Phase III trial of ibtrutinib in chronic lymphocytic leukemia (CLL). The trial compared inbrutinib to chlorambucil and showed a significant improvement in progression-free survival (PFS), which was the primary endpoint, and further an overall survival (OS) advantage for patients on the ibrutinib arm. Overall, ibrutinib was well tolerated according to Prof Hillmen. Recorded at the 2016 Annual Meeting of the British Society of Haematology (BSH) and International Society of Hematology (ISH), held in Glasgow, Scotland.
Nigel Russell, MD, from Nottingham University Hospitals NHS Trust, Nottingham, UK discusses the potential benefit of a higher dose of daunorubicin for a sub-group of acute myeloid leukemia (AML) patients with the FLT3-ITD mutation. This study was conducted as part of the AML17 trial and the abstract was presented at the 2016 World Congress of the International Society of Hematology (ISH) held in Glasgow, Scotland. Patients were randomized to receive two different doses of daunorubicin at induction therapy. Prof Russell discusses the initial report, which showed that there was no advantage to using the higher dose of daunorubicin. However, further…
Gilles Salles, MD, PhD, from South Lyon Hospital Complex, Lyon, France discusses the management of patients with follicular lymphoma in the first-line and relapsed setting. Prof Salles outlines the different treatment approaches for patients with limited stage and extended stage disease. For example, patients with limited stage disease may receive radiation therapy and for patients with a high-tumor burden, the standard of care has been chemotherapy plus an anti-CD20 such as rituximab. Prof Salles further discusses the option of a chemotherapy-free approach and the various options in the relapsed setting. Recorded at the 2016 Annual Meeting of the British Society…